Soleno Therapeutics, Inc.

As of September 19, 2025, Soleno Therapeutics, Inc. shows a mildly bearish trend with mixed signals from various indicators, despite a year-to-date return of 21.78% that outperforms the S&P 500.

As of September 12, 2025, Soleno Therapeutics, Inc. shows a mildly bearish trend with mixed signals across time frames, underperforming the S&P 500 recently but outperforming year-to-date.

As of August 6, 2025, Soleno Therapeutics, Inc. is rated as risky due to its overvaluation, negative performance metrics, and a stock return of 5.66% over the past year, significantly underperforming the S&P 500's 17.14% return.

As of April 22, 2025, the trend is bullish with strong indicators like a bullish MACD and Bollinger Bands, although caution is advised due to a bearish monthly RSI and mildly bearish KST.

As of March 2022, the management team of Soleno Therapeutics, Inc. includes Dr. Ernest Mario as the Independent Chairman and Dr. Anish Bhatnagar as the President and CEO, along with Independent Directors Mr. William Harris, Ms. Gwen Melincoff, Mr. Andrew Sinclair, and Dr. Birgitte Volck.

Soleno Therapeutics, Inc. is a micro-cap healthcare company focused on developing and commercializing devices and diagnostics for neonatology. As of March 2025, it reported a net profit loss of $44 million and has a market cap of approximately $3.91 billion.

As of Jun 18, Soleno Therapeutics, Inc. has a market capitalization of $3.91 billion, with net sales of $0.00 million and a net profit of -$198.22 million over the last four quarters. The company reported shareholder's funds of $245.11 million and total assets of $330.97 million as of Dec 24.